Protein injections in medicine
One day, medical compounds could be introduced into cells with the help of bacterial toxins
© MPI f. Molecular Physiology
As soon as bacteria have entered a host organism, they deploy their lethal weapon. Just like a syringe needle, they insert a channel through the outer protective layer of the host cell. The toxic protein contained in the capsule is then injected and attacks the cell’s structural framework. Within just a few minutes, the cell dies.
Raunser's team discovered this lethal mechanism by using cryo-electron microscopy, a technique employed by only a few research groups in the world. What this technique reveals is the three-dimensional structure of proteins in near-atomic resolution."
Targeted injection into body cells
Stefan Raunser’s researchers have now found a way to replace the toxin in the bacteria's nano-syringe with different proteins, and then inject them into cells. For the exchange to work, however, the proteins must fulfil certain criteria: they must be a particular size, be positively charged, and must not interact with the toxin capsule. “With this technique, we have taken the first step towards our ultimate goal of using these nano-syringes in medicine to introduce drugs into body cells in a targeted manner,” says Raunser, describing the successful research results.
To transfer its toxic charge into the host cell, the injection mechanism must first dock with the cell. But the bacteria must trick the host cell- by pretending that the toxin is a substance that can be safely absorbed – similar to the famous trojan horse trick. To do this, they have areas that are recognized by sensors on the cell surface.
“We are currently looking for the toxin's ‘docking stations’. Once we have found them and understood how the toxin binds to the cell surface, we aim to specifically modify the injection mechanism so that it can recognize cancer cells. We could then inject a killer protein exclusively into tumour cells. This would open up completely new possibilities in cancer medicine with minimal side effects,” predicts Raunser.
Original publication
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.